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Despite a 20-year-old guideline from the National Institutes of Health (NIH) Consensus Development Conference recommending
breast conserving surgery with radiation (BCSR) over mastectomy for woman with early-stage breast cancer (ESBC) because
it preserves the breast, recent evidence shows mastectomy rates increasing and higher-staged ESBC patients are more likely to
receive mastectomy. These observations suggest that some patients and their providers believe that mastectomy has advantages
over BCSR and these advantages increase with stage. These beliefs may persist because the randomized controlled trials (RCTs)
that served as the basis for the NIH guideline were populated mainly with lower-staged patients. Our objective is to assess the
survival implications associated with mastectomy choice by patient alignment with the RCT populations. We used instrumental
variable methods to estimate the relationship between surgery choice and survival for ESBC patients based on variation in local
area surgery styles. We ﬁnd results consistent with the RCTs for patients closely aligned to the RCT populations. However, for
patients unlike those in the RCTs, our results suggest that higher mastectomy rates are associated with reduced survival. We are
careful to interpret our estimates in terms of limitations of our estimation approach.
1.Introduction
Despiterandomizedcontrolledtrial(RCT)evidencesuggest-
ing survival equivalence between breast conserving surgery
with radiation (BCSR) and mastectomy for woman with
early-stage breast cancer (ESBC) [1–5] and a nearly 20-
year-old guideline from the National Institutes of Health
Consensus Development Conference recommending BCSR
over mastectomy because it preserves the breast [6], mas-
tectomy remains widely used [7, 8]. In fact, recent evidence
suggests that mastectomy rates are increasing [7, 9]. In
addition, higher-staged patients have been more likely to
receive mastectomy [8, 10]. These observations suggest that
some patients and their providers believe that mastectomy
has advantages over BCSR and these advantages increase
with stage. These beliefs may persist because the randomized
controlled trials (RCTs) that served as the basis for the NIH
guideline were populated mainly with lower-staged, younger
patients with few comorbidities [1–5].
In an analysis of the Surveillance, Epidemiology and End
Results (SEER)-Medicare observational database [11]f o r
ESBC patients using risk-adjustment methods, Keating et al.
found no diﬀerence in mortality risk for mastectomy relative
to BCSR for patients similar to those RCT samples (low-risk
tumors—stage I, little comorbid illness, and age ≤ 70) but
higher average mortality risk across all ESBC patients [8].2 International Journal of Surgical Oncology
These results imply a survival disadvantage for mastectomy
in patients with larger tumors, more comorbid illnesses, or
advanced age. In another risk-adjustment study using SEER-
Medicare data, Schonberg et al. found that mastectomy had
a survival disadvantage relative to BCSR that increased with
stage [10]. The risk-adjustment estimators used in both of
these analyses only adjusted for measured covariates. For
the estimates from these analyses to be unbiased it must be
assumedthatunmeasuredcovariatesaﬀectingsurgerychoice
are unrelated to survival [12, 13]. Keating et al. addressed
this issue by assessing whether their results were robust
to plausible imbalances in unmeasured covariates across
surgery choices. This analysis found, at the very least, no
evidenceofasurvivaladvantageassociatedwithmastectomy.
Instrument variable (IV) estimators also are available to
estimate treatment eﬀectiveness using observational data. IV
estimators are distinct from risk-adjustment estimators in
both the assumptions required to yield unbiased estimates
and in the interpretation of the eventual estimates [14–
18]. Risk-adjustment estimators assume that unmeasured
covariates aﬀecting treatment choice are unrelated to out-
comes and yield parameters that are properly interpreted
as estimates of the average treatment eﬀectfor the patients
that received treatment [12–16, 19, 20]. In contrast, IV
estimators yield estimates of a local average treatment
eﬀect, that is, the average eﬀect for the subset of patients
whose treatment choices were aﬀected by measured factors
called “instruments” [17, 21, 22]. IV estimators require
instruments with strong relationships with treatment choice
[23]. IV estimators work under the assumption that the
instruments used in the analysis have no direct eﬀect on
outcome and are independent of unmeasured covariates that
aﬀectoutcome.Basedonthisassumption,IVestimatorshave
beenlikenedtonaturalexperimentsintreatmentchoice[24].
Previous IV studies assessed the eﬀect of surgery choice for
ESBC patients but were limited geographically, had small
sample sizes, and used instruments with weak relationships
with surgery choice which resulted in imprecise parameter
estimates [15, 25, 26]. These pitfalls are avoided in this
study by using the SEER-Medicare database that included
ESBC patients from across the United States and by using
an instrument that strongly predicts surgery choice. Our
instrument exploits variation in local area physician practice
styles that has been shown to be a practical and rich source
for instrument development [15, 25, 27–31]. This approach
conjectures that patients residing in areas with physicians
that have preferences for a particular treatment are more apt
to receive that treatment and that unmeasured confounding
variables are unrelated to this access. Our algorithm to
measurelocalareapracticestyleshasbeenshowntoexplaina
larger portion of treatment variation than other approaches
and it eﬀectively balances measured confounding variables
[31, 32]. Mastectomy rates vary signiﬁcantly across the
United States [8], suggesting that local area practice styles for
ESBCpatients varyregionally.From1992–2002, mastectomy
rates for ESBC patients were 40.4% in Connecticut, 59.2 in
Utah, and 67.4% in Iowa [8].
2.MaterialsandMethods
2.1. Data and Sample. We used the 1992–2002 SEER-
Medicare databases and employed the same base inclu-
sion/exclusion criteria used in the Keating study [8, 11].
We identiﬁed 69,140 patients with stage I or II breast
cancer that were enrolled in parts A and B of fee-for-
service Medicare from 12 months before diagnosis through
9 months after diagnosis and had primary surgery (either
breast conserving surgery or mastectomy). To compute local
area mastectomy practice styles, we further excluded 1,005
patients that did not have a valid residence ZIP code, whose
residence ZIP code was outside of a SEER area, or lived in
an isolated island location within the Hawaii SEER registry.
The remaining 68,135 patients were used to estimate local
area mastectomy practice styles. Our dependent variable
was 7-year survival after diagnosis, and our focus was
comparing patients receiving mastectomy alone to those
receiving BCSR. To estimate the eﬀects of surgery choice on
survival we further excluded patients with less than 7 years
of followup (N = 32,683) and patients that either received
BCS without radiation or mastectomy with radiation (N =
6,777) leaving a ﬁnal estimation sample of 28,675 patients.
Models were also estimated using 6-year and 8-year survival
as robustness checks for our estimates.
2.2. Instrumental Variable Approach. We estimated local area
mastectomy practice styles using the driving area for clinical
care (DACC) method [31, 32]. All ESBC patients with valid
ZIP codes living in SEER areas (N = 68,135) were used. The
DACC method produces ZIP-speciﬁc practice style measures
that reﬂect the surgery choices for patients living within a
driving distance of each ZIP code. For each patient residence
ZIP code in the SEER-Medicare database, the DACC method
expanded driving times around the ZIP code to add ESBC
patients from additional ZIP codes until at least 50 patients
were identiﬁed. For the set of patients associated with each
Z I Pc o d ew et h e nc o m p u t e da na r e at r e a t m e n tr a t i o( A T R )
as the ratio of the proportion of ESBC patients receiving
mastectomy over the average predicted probability of the
ESBC patients in the area to receive mastectomy. Predicted
mastectomy probabilities for each patient were estimated
using a multivariate logistic model of mastectomy choice
over the 68,135 patients. The covariates used in this model
are described in the variable speciﬁcation section below. A
ZIP code with an ATR greater than 1 suggests a local area
practice style in which mastectomy is used at a rate higher
than average given the characteristics of the ESBC patients in
the area. An ATR less than 1 suggests a local area mastectomy
practice style less than average. Our IV estimates rest on
the assumption that the local area mastectomy practice style
reﬂected by the ATR has no direct eﬀect on survival other
than through surgery choice and is unrelated to unmeasured
covariates that aﬀect survival. We assessed whether our
results were robust to the number of ESBC patients used to
deﬁne areas around ZIP codes by using 25 and 100-patient
areas in separate analyses.
We applied the same two-stage least squares (2SLS)
instrumental variable method used by the previous ESBCInternational Journal of Surgical Oncology 3
studies [15, 25, 26, 33] and the seminal IV study in
healthservicesresearch[34].2SLSyieldsconsistentestimates
regardless of the underlying error distributions in contrast to
alternativeestimatorsthatrelyondistributionalassumptions
which yield inconsistent results if the assumptions are wrong
[35, 36]. In the ﬁrst stage of the 2SLS we estimated a model
of mastectomy choice across the 28,675 patients with 7 years
of followup that included, among other covariates described
below, the ATR-based instrument as an independent vari-
able. The instrument was speciﬁed in this ﬁrst stage model
using a series of binary variables for each patient that placed
the patient’s residence ZIP code ATR within the distribution
of ATRs across ZIP codes. For example, four binary variables
were constructed to represent the ﬁve ZIP code groups
deﬁned by quintile cutoﬀs of the ATRs across ZIP codes.
Patients were then assigned values for these binary variables
based on the ATR of their residence ZIP code relative to the
cutoﬀs (1 if patient residence ATR is within respective cut-
oﬀ points, zero otherwise). The second stage of the 2SLS
method was the 7-year survival model which includes all
the non-instrument covariates from the ﬁrst-stage model as
independent variables plus the predicted mastectomy choice
from the ﬁrst stage. As a result of this 2-stage process, the
parameter estimate associated predicted mastectomy choice
in the second stage will be estimated using only the variation
in mastectomy choice associated with the ATR instrument.
Under the IV assumption, this estimated parameter provides
a consistent estimate of the eﬀect of mastectomy on survival.
To assess the robustness of our ﬁndings to alternative
speciﬁcations, 2SLS models were run with the instrument
speciﬁed using median, quintile, decile, and vigintile cutoﬀs
of ATR values. 2SLS models were also estimated using the
full sample and for patient subsets deﬁned by stage, age,
and the alignment of patients with clinical trial eligibility.
In addition, we estimated a Hausman test statistic [37]
for each 2SLS speciﬁcation. 2SLS models in which the
instrument is speciﬁed using more than two groups are
also said to be overidentiﬁed and a Hausman test statistic
can be estimated to test the null hypothesis of whether
the patient groups identiﬁed using the instrument have no
empirical relationship with survival beyond the eﬀect of the
instruments on surgery choice. A large value of the Hausman
statistic rejects the null hypothesis. We also produced risk-
adjustment estimates using linear probability models to
provide a link between the risk-adjustment estimates from
previous research and our IV estimates from the 2SLS
estimator.
2.3. Variable Deﬁnitions. T h em u l t i v a r i a t el o g i s t i cm a s t e c -
tomy choice model used as the basis for ATR estimation
included patient covariates age at diagnosis, race, Hispanic
ethnicity,maritalstatus,diagnosisyear,cancerhistory,tumor
stage, tumor size, tumor grade, histology, estrogen and
progesterone receptor status, comorbid illness, adjuvant
chemotherapy use, and residence area average characteristics
(education, income, and living in a metropolitan area).
Characteristics of the hospital and physician were also
speciﬁed. All covariates above were speciﬁed consistently
with the Keating study and a full description of covariate
measurementcanbefoundthere[8].Thedependentvariable
in 2SLS and linear probability models was a binary variable
indicating7-yearsurvivalafterdiagnosis(1ifpatientsurvives
7 years, 0 otherwise). Surgery choice was deﬁned using a
binary variable (1 if patient received mastectomy, 0 if the
patient received BCSR) based on accepted deﬁnitions using
Medicare claims data [38–41]. In addition to the covariates
above, the 2SLS and linear probability models also speciﬁed
as covariates the proportion of ESBC patients that received
breast conserving surgery alone and proportion of patients
that received mastectomy plus radiation in the DACC-
deﬁned area around each patient residence ZIP code, and
binary variables for each SEER area. These covariates were
added to control for diﬀerences in the mix of ESBC patients
not receiving mastectomy alone and BCSR across areas.
3. Results
Table 1 contains summary statistics for the estimation sam-
ple by surgery (BCSR versus mastectomy) choice and by
the quintiles of the local area mastectomy practice style
measure. Relative to patients choosing BCSR, mastectomy
patients were generally older and sicker with higher-staged
disease, larger tumors, a higher percentage of poorly diﬀer-
entiated tumors, and they had more comorbid conditions.
In addition, patients receiving mastectomy were more apt
to see physicians with lower surgical volume, be treated in
smaller hospitals, live in nonmetro areas, and live in areas
with lower area median per capita income. In contrast, there
were few clear relationships between the patients grouped
by the ATR measure of local area mastectomy practice style
and measured covariates. From quintile 1 to quintile 5, the
percentage of patients receiving mastectomy increases from
37.9% to 68.6%. While variation in the measured covariates
is observed across the instrument-based quintile groups,
these diﬀerences mostly do not trend with the mastectomy
percentages across groups. Cochran-Armitage trend tests
show statistically signiﬁcant trends across the instrument
groups only for moderate tumor grade, unknown tumor
grade, hospital size, residence metro status, and area median
income [42, 43].
Figures 1(a) and 1(b) contain maps showing mastectomy
practice styles as measured by the area treatment ratios
(ATRs) across SEER areas over the period 1992–2002.
Clearly, substantial geographic variation in surgical choice
for ESBC patients exists after controlling for diﬀerences in
measured patient and provider characteristics. While some
SEER-area speciﬁc variation is visible (e.g., Connecticut with
few high mastectomy areas), both high and low mastectomy
areas exist within each SEER area.
Table 2 contains estimates of the eﬀect on 7-year survival
of mastectomy relative to BCSR. The table contains both
linear probability and IV estimates of the average 7-year
survival eﬀect of mastectomy relative to BCSR. As discussed
above, these IV estimates are average mastectomy survival
eﬀects for those patients whose surgery choices would have
diﬀered had they lived in an area with a diﬀerent local
area mastectomy practice style. Table 2 contains IV estimates
from the quintile instrument speciﬁcation. Estimates from4 International Journal of Surgical Oncology
Table 1: Early-stage breast cancer patient characteristics by surgery choice and instrumental variable-based patient quintile groups.
Covariates Surgery choice Instrument quintile groups
(higher area treatment ratio (ATR)→)
Variable Category Total BCSR Mastectomy P value
(χ2)
a 12345 P value
(χ2)
b
Column % Column %
Surgery Mastectomy 16,103 (56%) 0 100% na 37.9 50.2 59.7 65.7 68.6 <0.0001∗
BCSR 12,572 (44%) 100% 0% 62.1 49.8 40.3 34.3 31.4 <0.0001∗
Age 66–75 16,442 (57%) 63.9 52.2 <0.0001∗ 57.8 58.0 56.2 57.4 57.3 0.2251
76+ 12,233 (43%) 36.1 47.8 42.2 42.0 43.8 42.6 42.7 0.2251
Stage at diagnosis
Stage I 17,908 (62%) 75.1 52.6
<0.0001∗
63.8 62.0 62.4 60.8 63.2 0.0908
Stage IIa 7,700 (27%) 20.1 32.1 25.7 27.5 26.7 27.8 26.6 0.1261
Stage IIb 2,827 (10%) 4.4 14.1 9.7 9.6 10.1 10.6 9.3 0.4096
Stage IInos 240 (1%) 0.4 1.2 0.8 0.9 0.8 0.8 0.9 0.2169
Tumor size
≤10 8,797 (31%) 40 23.4
<0.0001∗
31.3 30.3 30.0 29.9 31.9 0.3633
11–20 11,958 (42%) 43.4 40.3 42.1 41.8 42.5 40.8 41.4 0.1152
>21 7,680 (27%) 16.2 35.1 25.8 27.1 26.7 28.5 25.8 0.2090
unknown 240 (1%) 0.4 1.2 0.8 0.9 0.8 0.8 0.9 0.2169
Grade
Well diﬀerentiated 4,751 (17%) 20.7 13.4
<0.0001∗
16.4 17.0 16.0 16.1 17.4 0.2426
Moderately diﬀerentiated 10,804 (38%) 39.9 35.9 39.3 38.4 37.3 36.6 36.6 0.0002∗
Poorly diﬀerentiated 6,718 (23%) 20.3 25.9 23.1 22.4 24.4 24.6 22.6 0.2138
Undiﬀerentiated/unknown 6,402 (22%) 19.1 24.9 21.2 22.1 22.3 22.7 23.3 0.0031∗
Comorbidity Below median 15,784 (55%) 58.1 52.7 <0.0001∗ 54.6 55.7 54.7 56.0 54.1 0.3759
Above median 12,891 (45%) 41.9 47.3 45.4 44.3 45.3 44.0 45.9 0.3759
Physician surgical
volume
Low volume 8,510 (30%) 26.0 32.6 <0.0001∗ 27.5 33.2 30.3 29.2 28.4 0.1447
High volume 20,165 (70%) 74.0 67.4 72.5 66.8 69.7 70.9 71.6 0.1447
Hospital bed size
≤350 15,461 (54%) 52.6 54.9 <0.0001∗ 54.8 57.7 56.8 52.1 47.9 <0.0001∗
351+ 13,214 (46%) 47.4 45.1 45.2 42.3 43.2 47.9 52.1 <0.0001∗
Residence area size Metro 24,530 (86%) 90.7 81.5 <0.0001∗ 91.0 87.8 78.8 77.4 92.7 <0.0001∗
Nonmetro 4,145 (14%) 9.3 18.5 9.0 12.2 21.2 22.6 7.3 <0.0001∗
Area median income
Above median 14,483 (51%) 53.9 47.8
<0.0001∗
52.4 51.9 41.8 50.2 56.3 0.0032∗
Below median 13,730 (48%) 44.6 50.4 46.9 46.3 57.3 46.6 42.2 0.0001∗
Missing 462 (2%) 1.5 1.7 0.7 1.8 0.9 3.2 1.5 <0.0001∗
aTest of diﬀerence in characteristic distribution between surgery choices.
bCochran-Armitage test of trend in characteristic value across patients grouped into quintiles based on local area mastectomy practice style measure. For
example, the P value for stage I tests whether a linear trend in stage I diagnoses exists across the instrument-based patient groups.
∗P<0.05.
the other instrument speciﬁcations are comparable in mag-
nitude and statistical signiﬁcance and are available from the
authors upon request. Our linear probability estimates for
the full sample and for the patient subsets by trial status
alignment are consistent with earlier risk-adjustment model
ﬁndings. Mastectomy has a statistically signiﬁcant negative
impact on 7-year survival for the full sample, but this
negative eﬀect appears to be stem mainly from the subset of
patients unlike those in the clinical trials. Higher-staged and
older patients had higher mastectomy rates and the negative
eﬀectofmastectomyonsurvivalestimatesincreasewithstage
and age.
The Chow-test [44] F-values in Table 2 test whether the
binaryvariablesrepresentingtheATRinstrumentintheﬁrst-
stage regression of 2SLS describe a statistically signiﬁcant
portion of the variation in mastectomy choice. Instruments
with a Chow-test F-statistic less than 10 are considered
“weak” in the IV literature [23]. Our Chow-test F-statisticsInternational Journal of Surgical Oncology 5
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Figure 1: Zip-code level maps of mastectomy local area treatment ratios for SEER areas in the eastern United States.
are much larger than 10 for both the full-sample and for
all-patient subsets. Based on the Hausman statistic, the
null hypothesis of whether the patient groups identiﬁed
using the ATR instrument have no relationship with survival
beyond the eﬀect of the instruments on surgery choice
was maintained for the full sample and all patient subsets.
The 2SLS estimate of the eﬀect of mastectomy on survival
for the entire sample was negative, statistically signiﬁcant,
and greater in magnitude than the estimate from the linear
probability model. As with the linear probability estimate,
the IV estimate for patients aligned with those in the clinical
trials revealed no relationship between surgery choice and
survival. The negative relationship between mastectomy and
survival stems mainly from patients unlike those in trials
whose IV estimate is negative and statistically signiﬁcant.
These estimates suggest that a 1 percentage point increase
in the mastectomy rate for the patients unlike those in the
trial populations would reduce the 7-year survival rate by .1
percentage points. When looking at patient subsets across
stage and age groups, the negative impact of mastectomy
on survival appears to increase with both age and stage
with statistically signiﬁcant negative relationships between
mastectomy use and survival for patients with stage IIa
tumors and patients 81 and older. In addition, the estimates
in Table 2 are robust to the number of patients used to
deﬁne treatment areas around each patient ZIP code (25 or
100) and whether 6-year or 8-year survival was used as an
endpoint. The estimates from these robustness checks are
available from the authors.
4. Discussion
Substantial regional variation in mastectomy rates for
patients with early stage breast cancer (ESBC) has been
documented. We used the portion of mastectomy rate
variation for ESBC patients 66 and older that was unrelated
tomeasuredcovariatesasameasureoflocalareamastectomy
style. The survival implications associated with variation in
local area mastectomy practice style for ESBC patients 66
and older were estimated in an instrumental variable (IV)
analysis. In general, IV estimators produce estimates which
representtheaverageeﬀectsoftreatmentonoutcomesforthe
subset of patients whose treatment choices were inﬂuenced
by the instrument speciﬁed in the analysis. Because IV
estimates are speciﬁc to patients whose treatment choices
areaﬀectedbythespeciﬁedinstrument,methodologistshave
cautioned about generalizing these results too broadly and
making inferences using IV estimates for policy questions
unrelated to the speciﬁed instrument [45]. In this paper our
local area mastectomy practice style instrument is directly
aligned to the policy question of whether higher mastectomy
rates aﬀect the survival of ESBC patients.
Our IV estimates suggest that higher mastectomy rates
described by diﬀerences in local area mastectomy practice
styles were associated with reduced survival relative to
BCSR for ESBC patients 66 and older. These estimates are
consistent with the risk-adjustment estimates from linear
probability models but are slightly larger. The existing NIH
guideline does not mention the possibility of mastectomy
survival disadvantages relative to BCSR. It suggests only
that for most ESBC patients mastectomy and BCSR are
equivalent with respect to survival and that mastectomy may
oﬀer advantages for higher-staged patients. However, recent
evidence on radiation eﬀectiveness from meta-analyses of
controlled trials and observational studies suggests that radi-
ation may have greater survival beneﬁts for ESBC patients
than what was presented in the original trials [46–48]. Our
IV estimates support the notion that radiation provides6 International Journal of Surgical Oncology
Table 2:Estimatesoftheeﬀectofmastectomyrelativetobreastconservingsurgerywithradiationon7-yearsurvivalbyestimatorandsample
subsets1.
Estimator
Estimation
Sample N
Mastectomy
percentage Linear probability estimates2 Instrumental variable estimates3
(1st–5th quintile
range)
Mastectomy eﬀect on 7-year
survival (std. error)
Instrument
chow test [44]
F-value
Over
identiﬁcation
test F-value
Mastectomy eﬀect
on 7-year survival
(std. error)
Full sample 28,675 56.2 −0.030
∗
264.01
∗ 0.60
−0.071
∗
(37.9–68.6) (0.006) (0.029)
Trial status comparable4
Yes 5,003 43.5 −0.001 50.43∗ 0.57 0.05
(25.5–57.0) (0.010) (0.05)
No 23,672 58.8 −0.037
∗
215.60∗ 0.38
−0.10
∗
(40.4–71.1) (0.006) (0.03)
Stage
Stage I 17,908 47.3 −0.017
∗
174.75∗ 0.93
−0.02
(28.2–61.3) (0.006) (0.03)
Stage IIa 7,700 67.2 −0.049
∗
63.02∗ 1.28
−0.15
∗
(50.3–78.5) (0.011) (0.06)
Stage IIb 2,827 80.2 −0.085
∗
23.81∗ 2.03
−0.22
(66.4–88.7) (0.023) (0.13)
Age
66–70 8,037 50.9 −0.010 75.53∗ 1.99 0.02
(33.5–64.3) (0.009) (0.05)
71–75 8,405 51.4 −0.016 81.82∗ 0.15
−0.05
(31.4–64.1) (0.010) (0.05)
76–80 6,611 57.5 −0.049
∗
69.94∗ 0.42
−0.11
(39.9–71.2) (0.012) (0.06)
81+ 5,622 69.2 −0.065
∗
37.15∗ 1.06
−0.19
∗
(52.3–78.6) (0.015) (0.09)
1All models also speciﬁed all measured covariates listed in the variable deﬁnition section and are more fully described in Keating et al. [8].
2Average treatment eﬀe c to nt h et r e a t e d( A T T ) .I nt h i sc a s e ,a v e r a g ee ﬀect of mastectomy on 7-year survival for those patients choosing mastectomy.
3Local average treatment eﬀect (LATE). The average eﬀect of mastectomy on 7-year survival for those patients whose mastectomy choice would have changed
w i t hl o c a la r e am a s t e c t o m yp r a c t i c es t y l e .
4ESBC patients with low-risk tumors (stage I), little comorbid illness, and age ≤ 70.
∗P<0.05.
greater survival beneﬁts than was originally anticipated from
the trial data especially for older patients with more severe
disease who are unlike those patients in the original trials.
In addition, it is has been shown that many BCSR patients
fail to complete their adjuvant radiation therapy [49]w h i c h
suggests that our results may understate the beneﬁts of BCSR
with a completed radiation course.
Of course, the inferences that can be made from our
estimatesdependonthevalidity of theassumptionsunderly-
ing our estimators. Risk-adjustment estimators assume that
unmeasured covariates related to surgery choice are unre-
lated to survival after controlling for measured covariates.
It is clear from the comparison of measured covariates in
Table 1 that the ESBC patients in our study that received
mastectomy tended to have higher-staged disease, less well-
diﬀerentiated tumors, and more comorbid conditions and
were older. These relationships suggest that other unmea-
sured factors related to disease severity such as tumor
location may be positively correlated with mastectomy
choice. If true, our risk-adjustment estimators may be biased
against mastectomy. Keating et al. showed that within plau-
sible relationships of unmeasured confounders and surgery
choice,though,thatamastectomysurvivaladvantagecannot
be supported from these data.
Our IV estimates of the eﬀect of mastectomy on survival
are consistent if the measure of local area mastectomy
practice style we used as an instrument has no direct
eﬀect on survival and is unrelated to other unmeasuredInternational Journal of Surgical Oncology 7
factors aﬀecting survival. As seen in Table 1, grouping
ESBC patients based on local area mastectomy practice style
clearly reduces the diﬀerences in measured confounders as
compared to grouping patients by surgery choice. While
some diﬀerences in measured covariates remained across the
patients grouped by our instrument, few substantial trends
remained across groups. However, it remains possible that
patients grouped by local area mastectomy practice style
are diﬀerent in unmeasured ways that are associated with
survival such as access to quality healthcare services. For
example, if patients living in high mastectomy areas have
less access to quality healthcare services, our IV estimates of
the eﬀect of mastectomy on survival biased be a biased low
(more negative) estimated of the true eﬀect for the ESBC
patients whose surgery choices would vary with local area
mastectomy practice style. Readers should also be cautioned
about generalizing our IV estimates to the ESBC patients
whose surgery choices would not have varied with the
mastectomypracticestyleintheareatheylived.Forexample,
of the ESBC patients not aligned with the trial populations
over 40% received mastectomy and nearly 29% received
BCSR regardless of where they lived. This suggests there are
ESBC patients that all providers believe are best-suited to a
particular surgery choice regardless of the provider’s practice
style. Because our sample was limited to patients aged 66 and
older, readers should also be cautioned about generalizing
our results to younger patients.
5. Conclusions
The randomized controlled trial evidence that led to the
guideline conclusion of survival equivalence between mas-
tectomy and breast conserving surgery with radiation
(BCSR) for patients with early-staged breast cancer (ESBC)
included mainly younger, stage I patients with few comorbid
conditions. As a result, a paucity of evidence is available
to judge the relative eﬀectiveness of ESBC surgery choices
for patients unlike those in the trials. Observed surgery
choices suggest that many providers and patients believe
that mastectomy is superior to BCSR for older and higher-
staged patients. However, there is no evidence to support or
reject these beliefs. In this paper we were able to describe the
relationship between surgery choice and survival for ESBC
patients aged 66 and older by exploiting the tremendous
amount of variation in local area mastectomy practice styles.
Our results suggest that reducing the mastectomy rate in
favor of BCSR may yield positive survival gains for higher-
staged older ESBC patients. These results are probably best-
applied to questions associated with changes in surgery
rates across populations, and readers are cautioned about
generalizing these results to all ESBC patients. Additional
studies are needed to conﬁrm these results. Future studies
based on observational data should include chart abstraction
components for a sample of patients to assess the validity of
the assumptions underlying the estimators used. Additional
controlled trials among patients unrepresented in the origi-
nal ESBC controlled studies may be needed to conﬁrm these
results.
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